NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Savas, Sevtap ^a,b,d   Azorsa, David O ^c   Jarjanazi, Hamdi ^a,b   Ibrahim Zada, Irada ^a,b   Gonzales, Irma M ^c   Arora, Shilpi ^c   Henderson, Meredith C ^c   Choi, Yun Hee ^a,e   Briollais, Laurent ^a   Ozcelik, Hilmi ^a,b   Tuzmen, Sukru ^c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN 2; COLLAGEN TYPE 13 ALPHA 1; ELL ASSOCIATED FACTOR 2; LIPIN 2; MEMBRANE PROTEIN; MEVINOLIN; MITOCHONDRIAL RIBOSOMAL PROTEIN S31; NEUROPHILIN 1; PARVIN BETA; PROTEIN KINASE A ANCHOR PROTEIN 7; SIMVASTATIN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 2; UNCLASSIFIED DRUG; EAF2 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

AKAP7 GENE; ANK2 GENE; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN; CELL STRAIN HCT116; CELL STRAIN NCI60; COL13A1 GENE; CONTROLLED STUDY; CYTOTOXICITY; EAF2 GENE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN CELL; INTRON; LPIN2 GENE; MRPS31 GENE; NRP1 GENE; PARVB GENE; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STEAP2 GENE; CELL STRAIN HT29; DRUG RESISTANCE; FACTUAL DATABASE; GENETICS; GENOMICS;

DATABASES, FACTUAL; DRUG RESISTANCE, NEOPLASM; GENOMICS; HCT116 CELLS; HT29 CELLS; HUMANS; LOVASTATIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIMVASTATIN; TRANSCRIPTION FACTORS;

EID: 79953691809     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018306     Document Type: Article

References (49)

1. Lennernas H, Fager G, (1997) Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 32: 403-425.
2. Kang S, Kim ES, Moon A, (2009) Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep 21: 1317-1322.
3. Gauthaman K, Fong CY, Bongso A, (2009) Statins, stem cells, and cancer. J Cell Biochem 106: 975-983.
4. Gauthaman K, Manasi N, Bongso A, (2009) Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol 157: 962-973.
5. Ogunwobi OO, Beales IL, (2008) Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 103: 825-837.
6. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C, (2008) HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem Biophys Res Commun 374: 309-314.
7. Freeman MR, Solomon KR, (2004) Cholesterol and prostate cancer. J Cell Biochem 91: 54-69.
8. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR, (2002) Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 62: 2227-2231.
9. Hager MH, Solomon KR, Freeman MR, (2006) The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 9: 379-385.
10. Patra SK, (2008) Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 1785: 182-206.
11. Abraham J, Earl HM, Pharoah PD, Caldas C, (2006) Pharmacogenetics of cancer chemotherapy. Biochim Biophys Acta 1766: 168-183.
12. Cascorbi I, (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112: 457-473.
13. Shoemaker RH, (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
14. Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, et al. (2006) Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 5: 2613-2623.
15. Jarjanazi H, Kiefer J, Savas S, Briollais L, Tuzmen S, et al. (2008) Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine. Hum Mutat 29: 461-467.
16. Savas S, Briollais L, Ibrahim-zada I, Jarjanazi H, Choi YH, et al. (2010) A whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca2+ signaling in selenium resistance. PLoS One 5: e12601.
17. Eng L, Ibrahim-Zada I, Jarjanazi H, Savas S, Meschian M, et al. (2011) Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. BMC Med Genomics 4: 18.
18. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
19. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
20. Hochberg Y, Benjamini Y, (1990) More powerful procedures for multiple significance testing. Stat Med 9: 811-818.
21. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311.
22. Wheeler DL, Church DM, Lash AE, Leipe DD, Madden TL, et al. (2002) Database resources of the National Center for Biotechnology Information: 2002 update. Nucleic Acids Res 30: 13-16.
23. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE, (1981) Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41: 1751-1756.
24. Fogh J, Trempe G, (1975) New human tumor cell lines. In: Fogh J, editors. Human tumor cells in vitro New York Plenum Press pp. 115-159.
25. Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, et al. (2009) Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 7: 43.
26. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
27. Tuzmen S, Kiefer J, Mousses S, (2007) Validation of short interfering RNA knockdowns by quantitative real-time PCR. Methods Mol Biol 353: 177-203.
28. Guirland C, Suzuki S, Kojima M, Lu B, Zheng JQ, (2004) Lipid rafts mediate chemotropic guidance of nerve growth cones. Neuron 42: 51-62.
29. Ylonen R, Kyronlahti T, Sund M, Ilves M, Lehenkari P, et al. (2005) Type XIII collagen strongly affects bone formation in transgenic mice. J Bone Miner Res 20: 1381-1393.
30. Arden SD, Roep BO, Neophytou PI, Usac EF, Duinkerken G, et al. (1996) Imogen 38: a novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient. J Clin Invest 97: 551-561.
31. Maurus D, Heligon C, Burger-Schwarzler A, Brandli AW, Kuhl M, (2005) Noncanonical Wnt-4 signaling and EAF2 are required for eye development in Xenopus laevis. Embo J 24: 1181-1191.
32. Hahn J, Xiao W, Jiang F, Simone F, Thirman MJ, et al. (2007) Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL-binding domain. Prostate 67: 146-153.
33. Xiao W, Zhang Q, Habermacher G, Yang X, Zhang AY, et al. (2008) U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia. Oncogene 27: 1536-1544.
34. Mohler PJ, (2006) Ankyrins and human disease: what the electrophysiologist should know. J Cardiovasc Electrophysiol 17: 1153-1159.
35. Gray PC, Scott JD, Catterall WA, (1998) Regulation of ion channels by cAMP-dependent protein kinase and A-kinase anchoring proteins. Curr Opin Neurobiol 8: 330-334.
36. Peterfy M, Phan J, Xu P, Reue K, (2001) Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet 27: 121-124.
37. Al-Mosawi ZS, Al-Saad KK, Ijadi-Maghsoodi R, El-Shanti HI, Ferguson PJ, (2007) A splice site mutation confirms the role of LPIN2 in Majeed syndrome. Arthritis Rheum 56: 960-964.
38. Ohgami RS, Campagna DR, McDonald A, Fleming MD, (2006) The Steap proteins are metalloreductases. Blood 108: 1388-1394.
39. Porkka KP, Helenius MA, Visakorpi T, (2002) Cloning and characterization of a novel six-transmembrane protein STEAP2, expressed in normal and malignant prostate. Lab Invest 82: 1573-1582.
40. Korenbaum E, Olski TM, Noegel AA, (2001) Genomic organization and expression profile of the parvin family of focal adhesion proteins in mice and humans. Gene 279: 69-79.
41. Mongroo PS, Johnstone CN, Naruszewicz I, Leung-Hagesteijn C, Sung RK, et al. (2004) Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer. Oncogene 23: 8959-8970.
42. Vree TB, Dammers E, Ulc I, Horkovics-Kovats S, Ryska M, et al. (2003) Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers:gut hydrolysis of lovastatin is twice that of simvastatin. Scientific World Journal 3: 1332-1343.
43. Kodach LL, Bleuming SA, Peppelenbosch MP, Hommes DW, van den Brink GR, et al. (2007) The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 133: 1272-1281.
44. Gbelcova H, Lenicek M, Zelenka J, Knejzlik Z, Dvorakova G, et al. (2008) Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 122: 1214-1221.
45. Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, et al. (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703-710.
46. Tomiyama N, Matzno S, Kitada C, Nishiguchi E, Okamura N, et al. (2008) The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull 31: 369-374.
47. Martirosyan A, Clendening JW, Goard CA, Penn LZ, (2010) Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 10: 103.
48. Lewis KA, Holstein SA, Hohl RJ, (2005) Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res 29: 527-533.
49. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, et al. (2001) Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19: 81-83.